ReviewFrontiers in oncology2022
PSMA PET in Imaging Prostate Cancer.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06209853 (Correlation Between Prostate-Specific Antigen), which is not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Correlation Between Prostate-Specific Antigen (PSA) Levels and Fluorine-18 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography (F-18 PSMA PET/CT) Scan Findings in Patients With Prostate Cancer
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Head-to-head comparison ofProstate cancer and prostatic diseases · 2023Pooled it
- Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- [Tomography (Ann Arbor, Mich.) · 2022Trial
- PROspective Prostate Cancer Infrastructure: study protocol for the ProPCI 'trials within cohorts' study.BMJ open · 2026Observational
- Review
- Diagnostic Accuracy of [Cancers · 2026Article
- Review
- Solitary Testicular Metastasis From Ductal Prostate Cancer 5 Years After Radical Prostatectomy: A Case Report.Case reports in urology · 2026Article
- Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer.Oncology and therapy · 2025Review
- The role of PSMA PET/CT in identifying benign and malignant intracranial lesions in patients with prostate cancer.Clinical imaging · 2025Article
- Primary Score as a Predictive Marker in Intermediate-Risk Prostate Cancer: Insights from PSMA PET/CT Imaging.Nuclear medicine and molecular imaging · 2025Article
- Detection Accuracy of [World journal of nuclear medicine · 2025Article
- Theranostic Nanoprobes Assisted NIR-II Fluorescence Imaging for Efficient Angiography and Tumor Therapy.ACS omega · 2025Article
- Achieving Complete Response in Metastatic Prostate Cancer With Triplet Therapy and Local Radiation: A Case Report.Cureus · 2025Article
- PRIMARY scoring in 68Ga-PSMA PET/CT: correlation with prostate cancer risk groups and its potential impact on active surveillance.Annals of nuclear medicine · 2025Article
- Genomic characterization of metastatic patterns in prostate cancer using circulating tumor DNA data from the SCRUM-Japan MONSTAR SCREEN project.The journal of liquid biopsy · 2025Article
- Solitary testicular metastasis post-prostatectomy for prostatic ductal adenocarcinoma: case report and literature review.Frontiers in oncology · 2025Article
- Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer.Frontiers in oncology · 2025Review
- Recommendations from Imaging, Oncology, and Radiology Organizations to Guide Management in Prostate Cancer: Summary of Current Recommendations.Radiology. Imaging cancer · 2025Review
- Advanced single-cell and spatial analysis with high-multiplex characterization of circulating tumor cells and tumor tissue in prostate cancer: Unveiling resistance mechanisms with the CoDuCo in situ assay.Biomarker research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After prostate malignancy diagnosis, precise determination of disease extent are fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the disease, the longer the survival in many cases. National and international guidelines are based on "classic" imaging technics combining radiological and nuclear medicine scans like CT, MRI and bone scintigraphy (BS). The most recent nuclear medicine development is the prostate specific membrane antigen (PSMA) PET and is emerging as the most promising tool of medical imaging, gaining ground every day. Nevertheless, the different onset among multiple studies fails to establish a worldwide admission and incorporation of this technique in guidelines and its position in workaday medical algorithms. It seems that the medical community agrees not to utilize PSMA PET for low-risk patients; intense debate and research is ongoing for its utility in intermediate risk patients. Contrariwise, in high-risk patients PSMA PET is confirmed outperforming CT and BS combined. Additionally, irrespectively to their castration status, patients with biochemical failure should be referred for PSMA PET. Even though PSMA PET reveals more extended disease than expected or exonerates equivalent lesions, thus impacting treatment optimization. Studies being in progress and future trials with clarify whether PSMA PET will be the new gold standard technic for specific groups of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.